Hiroshi Mikitani, founder of Rakuten Group, is dedicating 20% of his time to Rakuten Medical, a US-based biotech startup focusing on cancer treatments, despite his other business incurring significant losses.

The healthtech startup is already generating revenue and is trialing its drugs globally, while having received a fast-track designation from US regulators.